Full Press Release Details
NEW YORK, NY--(Marketwire - August 1, 2007) - Daxor Corporation (AMEX: DXR), a medical
instrumentation and biotechnology company, today announced the publication
of the article "Measurement of Blood Volume at Bedside: New Era in
Critical Care Medicine" in the Internet Journal of Emergency and Intensive
Care Medicine (2007; Volume 10, Number 1).
Dr. Bobbak Vahid, from the Department of Pulmonary and Critical Care
Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania,
is cited as the main author. The Internet Journal of Emergency and
Intensive Care Medicine is a peer-reviewed on-line journal.
The study article discusses that, "Accurate assessment of volume status of
the critically care ill patient in the intensive care unit is a challenging
task facing intensivists each day." Additionally, surrogate measurements
compared to a measured blood volume with Daxor's Blood Volume Analyzer has
shown to be accurate "less than 50%."
"What is important to note is that this article was generated based upon
study data generated by other medical institutions," stated John
Reyes-Guerra, Daxor's V.P. of Marketing and Sales. Mr.
Reyes-Guerra also noted that, "Word is spreading through peer-reviewed
articles, such as this article and other articles which were recently
published in the Journal of American Medical Sciences, which provide proof
sources to physicians who have not yet embraced or question the efficacy of
the critical diagnostic information that the BVA-100 provides. These type
of evidenced-based articles help to change the paradigm of physicians who
rely on surrogate or guesstimate methods, and contribute to the Blood
Volume Analyzer BVA-100 becoming a new standard of care."
Blood volume estimates by extremely invasive procedures, various physical
signs and symptoms and surrogate measurements are often the standard of
care because of the past inability of clinicians to have access to an
accurate, repeatable, FDA approved diagnostic instrument. With the
introduction of Daxor's BVA-100, studies have shown to influence changes in
treatment decisions 20% to 35% of patients.
Daxor Corporation manufactures and markets the BVA-100, a semi-automated
Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex,
Daxor's single use diagnostic kit. For more information regarding Daxor
Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website
Contact Information: Contact Information:
Chief Operating Officer